Plaque Psoriasis

In a new interview at the DERM2025 Conference, Stein Gold highlighted several topical options for patients with psoriasis outside of topical steroids.

This interview segment highlights additional information on the 16-week risankizumab data from the phase 4 UnlIMMited study.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.

This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.

In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.

Based on reduced FOXP3+ expression in patients, investigators have drawn a strong correlation between MetS due to psoriasis and immune dysregulation.

Findings suggest pediatric patients with guttate or inverse psoriasis may warrant evaluation for pharyngeal or anogenital bacterial infections.

Overall, older treatment strategies such as methotrexate and phototherapy still led the way for cost-effectiveness.

This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

More than 60% of patients with psoriasis achieved PASI 100 at week 16 with bimekizumab and maintained skin clearance up to 4 Years.

This analysis highlights the risk of superficial fungal infections among patients with moderate-to-severe psoriasis given biologics such as IL-17 inhibitors.

This analysis highlights the observed risk of developing psoriasis when using dupilumab to treat atopic dermatitis.

Recent research comparing the two diseases against a sample of the general population has indicated a substantially higher mortality risk and rate in GPP than in plaque psoriasis.

Study findings highlight a heightened risk of MetS in patients with psoriasis, especially those with more severe disease based on PASI scores.

Research has indicated a suggestive association between predicted psoriasis and uterine corpus cancer in women and prostate cancer in men.

This interview from the 2025 New Wave Dermatology Conference features DiRuggiero discussing challenging psoriasis cases and tips for healthcare providers.

Discover innovative treatments for plaque psoriasis that cater to diverse skin tones, offering effective relief without the risk of discoloration.

This approval of roflumilast foam as a once-daily topical treatment for psoriasis of the scalp and body followed the phase 3 ARRECTOR study findings.